MART-1 is an endogenous melanoma-associated antigen that can be used in the development of vaccines to induce an immune response against cancerous cells expressing melanoma antigens. Vaccines using MART-1 conjugates have shown some anticancer chemotherapeutic efficacy in clinical trials.
| Purity | ≥95% |
|---|---|
| Formula | C37H67N9O11 |
| Formula Wt. | 814.0 |
| Synonym | MART-1 (27-35) |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | M1649 Info Sheet PDF |
|---|
Chodon T, Comin-Anduix B, Chmielowski B, et al. Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma. Clin Cancer Res. 2014 May 1;20(9):2457-65. PMID: 24634374.
Romano E, Michielin O, Voelter V, et al. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med. 2014 Apr 12;12:97. PMID: 24726012.
